THE APEX TIMES
A new industry forecast centers on next-generation delivery technologies as biologics and gene therapies expand, while companies including AbbVie, Moderna, Pfizer and Novartis invest in platforms aimed at improving patient access and product differentiation.
Drug and gene delivery devices could become a fast-growing market, according to a new global strategic business report published through a financial news feed. The report projects the category expanding at an 8.1% compound annual growth rate (CAGR), reaching $1.2 billion by 2032.
The forecast ties growth to demand for delivery systems that do more than transport medicine. It highlights “next-gen delivery platforms” positioned to differentiate biologics, support precision therapies, and potentially help extend the commercial life of products by changing how and where they are administered.
Beyond clinical performance, the report frames usability and patient experience as competitive factors. It points to the growing push for non-invasive approaches and “connected care,” suggesting delivery technologies that are easier to administer outside traditional clinical settings, while also enabling digital monitoring or integration.
In the report’s framing, multiple large life sciences companies are accelerating efforts in related areas, with AbbVie, Moderna, Pfizer and Novartis named as contributors to momentum. However, the announcement does not provide company-by-company details, timelines, or specific device programs tied to any one firm.
For Pfizer, the mention is consistent with broader industry trends that have increasingly focused on how therapies are delivered, especially as biologics and gene-based treatments move beyond one-size-fits-all administration. Still, the post does not describe Pfizer’s specific device strategy, partnerships, or product pipeline items in this market.
Industry context: delivery devices sit at the intersection of therapeutics and patient-facing technology. As therapies become more specialized, manufacturers seek systems that can improve reliability, reduce administration burden, and potentially support adherence. Connected-care concepts can also matter for manufacturers that want tighter visibility into treatment workflows, even when patients are not in a clinic.
Notably, the post’s disclosed content is limited to high-level market outlook language. It does not provide methodological details behind the forecast, such as the underlying segment definitions (for example, what is included as a “device”), nor does it break out which therapeutic areas drive the $1.2 billion estimate.
What to watch next is whether companies named in the report, including Pfizer, provide more specific disclosures about delivery platforms, trial results, device approvals, or commercial rollouts. Investors and health systems may also look for evidence that non-invasive and connected-care delivery approaches can deliver measurable benefits in real-world administration and patient outcomes.
The beverage alcohol maker said an executive will discuss company developments at the 2026 gathering of consumer and retail investors.
The alternative asset manager said its president and chief operating officer is scheduled to present at the Goldman Sachs event on Wednesday, according to a new announcement filed through market channels.
UnitedHealth slid after the Centers for Medicare and Medicaid Services proposed expanding Medicare Advantage audits and potentially recovering plan overpayments dating back to 2018, a move other managed-care and pharmacy-linked insurers also faced.
The tech investor argues that regulatory or compliance pressure may force NVIDIA’s latest GPUs to include buyer verification checks that amount to a biometric-style “kill switch,” aiming to deter resale or diversion to restricted end users.
A recent market note argues that Alphabet’s platform could offer better five-year stock upside than Amazon, pointing to how AI is being embedded into cloud products and distribution. The piece stops short of providing new, primary data on near-term earnings.
Ahead of its late-Tuesday results, Nvidia is set to update investors on performance for its fiscal third quarter, a key checkpoint for demand trends in AI-linked data center spending.
In results for its third quarter of fiscal 2027, NVIDIA said revenue rose more than twofold year over year, with data center revenue accounting for nearly all of the company’s growth.
Broad-market indexes slipped on Tuesday, with Nvidia’s upcoming earnings acting as a key weight on sentiment, according to Yahoo Finance.
A new Yahoo Finance comparison frames Eaton’s electrical exposure as a lever for data-center growth, while casting Honeywell’s strategy shift toward automation as a tradeoff that could change how investors view risk in 2027.
In a Q3 2026 earnings call posted by Yahoo Finance, Home Depot highlighted a CEO handoff and lowered growth expectations tied to its SRS metric, indicating a more cautious near-term view of demand.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...